Recomendaciones para el diagnóstico y tratamiento de las vasculitis asociadas a anticuerpos anticitoplasma de neutrófilo.

Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is characterised by small vessel necrotising inflammatory vasculitis. Prior to immunosupressant therapy availability it usually led to a fatal outcome. Current treatment has changed ANCA-associated vasculitis into a condition with...

Descripción completa

Detalles Bibliográficos
Autores: Morales, Enrique, Rúa Figueroa, Iñigo, Callejas Rubio, José Luis, Ávila Bernabéu, Ana, Blanco Alonso, Ricardo, Cid Xutglà, M. Cinta, Manrique Escola, Joaquín, Narváez García, Francisco Javier, Sopeña, Bernardo, Quintana Porras, Luis F., Romero Yuste, Susana, Solans Laqué, Roser
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/220652
Acceso en línea:https://hdl.handle.net/2445/220652
Access Level:acceso abierto
Palabra clave:Neutròfils
Immunosupressió
Autoanticossos
Inflamació
Vasculitis
Neutrophils
Immunosuppression
Autoantibodies
Inflammation
Descripción
Sumario:Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is characterised by small vessel necrotising inflammatory vasculitis. Prior to immunosupressant therapy availability it usually led to a fatal outcome. Current treatment has changed ANCA-associated vasculitis into a condition with a significant response rate, although with a not negligible relapse occurrence and cumulative organ lesions, mostly due to drug-related toxicities. The use of glucocorticoids, cyclophosphamide and other immunosupressants (such as azathioprine, mychophenolate and methotrexate) was optimised in a series of clinical trials that established the treatment of reference. In recent years, a better knowledge of B lymphocyte function and the role of complement inhibition has transformed the course of this disease while minimising treatment-related adverse effects. This multidisciplinary document of recommendations is based on the consensus of three scientific societies (Internal Medicine, Nephrology and Rheumatology) and on the best available evidence on diagnosis, treatment and follow-up of patients with ANCA-associated vasculitis, including some special situations. The aim of this document is to provide updated information and well-grounded clinical recommendations to practising physicians as to how to improve the diagnosis and treatment outcome of our patients.